Spots Global Cancer Trial Database for A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
Official Title: A Phase I/IIa Study on Dose-escalation and Extension of Recombinant Humanized Type II CD20 Monoclonal Antibody MIL62 Injection Combined With BTK Inhibitor Orelabrutinib in the Treatment of Recurrent/Refractory CD20+B-cell Lymphoma
Study ID: NCT04304040
Study Description
Brief Summary: Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Beijing Hospital, Beijing, Beijing, China
Beijing Shijitan hospital, capital medical university, Beijing, Beijing, China
Cancer hospital, Chinese academy of medical sciences, Beijing, Beijing, China
Affiliated Hospital of Hebei University, Baoding, Hebei, China
Henan Tumor Hospital, Zhengzhou, Henan, China
Hunan Cancer Hospital, Changsha, Hunan, China
First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
The First Hospital of Jilin University, Changchun, Jilin, China
Tianjin People's Hospital, Tianjin, Tianjin, China
Contact Details
Name: Yuankai Shi, PhD
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
